Global and regional burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2019: results from the Global Burden of Disease study 2019
单位:[1]Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Capital Medical University, Beijing, China[2]National Center for Respiratory Medicine.Institute of Respiratory Medicine, Chinese Academy of Medical Sciences.National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, Beijing, China[3]State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, National Centre for Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China[4]Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA[5]Department of Pulmonary and Critical Care Medicine, China-Japan Friendship School of Clinical Medicine, Peking University, Beijing, Beijing, China[6]Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Background Interstitial lung disease (ILD) and pulmonary sarcoidosis are common respiratory diseases with a heterogeneous distribution worldwide. The global burden and temporal trends of ILD and sarcoidosis are rarely explored. Methods Using the classification 'ILD and pulmonary sarcoidosis' from the Global Burden of Disease 2019 dataset, we described the age-standardised rates of incidence, mortality, disability-adjusted life-years (DALYs), and their average annual percentage change from 1990 to 2019 by sex, Sociodemographic Index (SDI) and region. Results In 2019, the global incidence and mortality of ILD and pulmonary sarcoidosis were 24.2 million and 169 833 cases, respectively. From 1990 to 2019, the global incidence, deaths and DALYs due to ILD and pulmonary sarcoidosis increased by 118.6%, 166.63% and 122.87% respectively. The global incidence of ILD and pulmonary sarcoidosis was higher in men and was mainly concentrated among persons aged 70-79 of both sexes. Significant regional differences could be seen in the disease burden of ILD and pulmonary sarcoidosis: since 2006, high-SDI regions had higher age-standardised incidence rates but lower age-standardised death rates compared with the low-SDI regions. Conclusions Our study suggests the incidence, mortality and DALYs from ILD and pulmonary sarcoidosis are increasing globally. To reduce the ongoing burden of this condition, early diagnosis and treatment are vital, and more targeted and specific strategies should be established in high-burden regions. Differences in incidence and mortality across regions may reflect the influence of genetic, environmental, diagnostic, pharmacotherapeutic, and health system factors.
基金:
Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences [2018--I2M-1-001]; Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences [2019PT320021]; National Natural Science Foundation of China [81870056]
第一作者单位:[1]Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Capital Medical University, Beijing, China[2]National Center for Respiratory Medicine.Institute of Respiratory Medicine, Chinese Academy of Medical Sciences.National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, Beijing, China[3]State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, National Centre for Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
共同第一作者:
通讯作者:
通讯机构:[1]Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Capital Medical University, Beijing, China[2]National Center for Respiratory Medicine.Institute of Respiratory Medicine, Chinese Academy of Medical Sciences.National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, Beijing, China[5]Department of Pulmonary and Critical Care Medicine, China-Japan Friendship School of Clinical Medicine, Peking University, Beijing, Beijing, China[6]Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[*1]Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Capital Medical University, Beijing 100029, China
推荐引用方式(GB/T 7714):
Ma Xiaoqian,Zhu Lili,Kurche Jonathan S,et al.Global and regional burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2019: results from the Global Burden of Disease study 2019[J].THORAX.2022,77(6):596-605.doi:10.1136/thoraxjnl-2020-216732.
APA:
Ma Xiaoqian,Zhu Lili,Kurche Jonathan S,Xiao Huijuan,Dai Huaping&Wang Chen.(2022).Global and regional burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2019: results from the Global Burden of Disease study 2019.THORAX,77,(6)
MLA:
Ma Xiaoqian,et al."Global and regional burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2019: results from the Global Burden of Disease study 2019".THORAX 77..6(2022):596-605